A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Neoplasms, Lymphoma, Non-Hodgkin

In brief

PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.

Key facts

Study ID

NCT00141297

Run by

Pfizer

People needed

74

Starts

2004-09-01

Expected to finish

2014-12-01

Last updated by the study team

2016-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb
• Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.
• Patients may have to have tumor biopsy before and after treatment.

You may not qualify if…

• Prior stem cell or bone marrow transplant
• Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse
• Active or unstable cardiac disease or history of heart attack within 6 months

Where it is running

• Karmanos Cancer Institute — Detroit, Michigan, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Abramson Cancer Center Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Pharmacy/PCAM/West Pavillion — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.